The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Cisplatin Nephrotoxicity: A Review
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thadhani, R., Pascual, M., & Bonventre, J. V. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342207 · Cited by 1,417
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
Arany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Acute renal failure: definitions, diagnosis, pathogenesis, and therapy
Schrier, R. W., Wang, W., Poole, B., & Mitra, A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22353 · Cited by 683
Acute renal failure: definitions, diagnosis, pathogenesis, and therapy
Schrier, R. W., Wang, W., Poole, B., & Mitra, A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422353 · Cited by 642
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Lieberthal, W., Triaca, V., & Levine, J. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.270.4.f700 · Cited by 449
Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2
Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H.-J., Haier, J., Jaehde, U., Zisowsky, J., & Schlatter, E. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61234-5 · Cited by 448
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment
Jang, K.-J., Mehr, A. P., Hamilton, G. A., McPartlin, L. A., Chung, S., Suh, K.-Y., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40049b · Cited by 849
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Engineered In Vitro Disease Models
Benam, K. H., Dauth, S., Hassell, B., Herland, A., Jain, A., Jang, K.-J., Karalis, K., Kim, H. J., MacQueen, L., Mahmoodian, R., et al. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040418 · Cited by 554
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity
Karasawa, T., & Steyger, P. S. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.06.012 · Cited by 475
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Volarevic, V., Djokovic, B., Jankovic, M. G., Harrell, C. R., Fellabaum, C., Djonov, V., & Arsenijevic, N. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0518-9 · Cited by 438
Bodei, L., Cremonesi, M., Ferrari, M., Pacifici, M., Grana, C. M., Bartolomei, M., Baio, S. M., Sansovini, M., & Paganelli, G. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0778-1 · Cited by 428
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.139 · Cited by 399
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Recent development of biotin conjugation in biological imaging, sensing, and target delivery
Ren, W. X., Han, J., Uhm, S., Jang, Y. J., Kang, C., Kim, J.-H., & Kim, J. S. (2015) · Chemical Communications · doi:10.1039/c5cc03075g · Cited by 393
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 384
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Copper metabolism as a unique vulnerability in cancer
Shanbhag, V. C., Gudekar, N., Jasmer, K., Papageorgiou, C., Singh, K., & Petris, M. J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118893 · Cited by 368
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis
Vyas, D., Laput, G., & Vyas, A. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s60114 · Cited by 310
Nanotechnological carriers for cancer chemotherapy: The state of the art
Estanqueiro, M., Amaral, M. H., Conceição, J., & Sousa Lobo, J. M. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.12.041 · Cited by 298
Ohta, S. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797052664 · Cited by 296
Testicular Cancer Survivorship: Research Strategies and Recommendations
Travis, L. B., Beard, C., Allan, J. M., Dahl, A. A., Feldman, D. R., Oldenburg, J., Daugaard, G., Kelly, J. L., Dolan, M. E., Hannigan, R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq216 · Cited by 294
Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G., & Berghmans, S. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.249 · Cited by 275
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Biomarkers of Acute Kidney Injury
Edelstein, C. L. (2008) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.04.003 · Cited by 272
Yang, K., Yu, G., Yang, Z., Yue, L., Zhang, X., Sun, C., Wei, J., Rao, L., Chen, X., & Wang, R. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202103721 · Cited by 255
Shahid, F., Farooqui, Z., & Khan, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.009 · Cited by 166
Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems
Gyanani, V., Haley, J. C., & Goswami, R. (2021) · Pharmaceuticals · doi:10.3390/ph14090835 · Cited by 118
El-Sayed, S. M., El-Naggar, M. E., Hussein, J., Medhat, D., & El-Banna, M. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.110465 · Cited by 56
Rovetta, F., Stacchiotti, A., Consiglio, A., Cadei, M., Grigolato, P. G., Lavazza, A., Rezzani, R., & Aleo, M. F. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.11.008 · Cited by 55
“CisPt-induced nephrotoxicity is actually considered a complex event, linked to different molecular pathways and to specific genetic modulations [4,5].”
BackgroundMelatonin ameliorates the drug induced nephrotoxicity: Molecular insights
Raza, Z., & Naureen, Z. (2020) · Nefrología · doi:10.1016/j.nefro.2019.06.009 · Cited by 43
Kimura, H., Nakamura, H., Goto, T., Uchida, W., Uozumi, T., Nishizawa, D., Shinha, K., Sakagami, J., & Doi, K. (2024) · Lab on a Chip · doi:10.1039/d3lc00934c · Cited by 20
Metadata
- Authors
- Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K.
- Venue
- The American Journal of the Medical Sciences
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 334
- Issue
- 2
- Pages
- 115-124
- ISSN
- 0002-9629 (ISSN-L)
- OpenAlex
- W2127618819
- Cited by
- 1,251
- References
- 54
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.